|
Orthologous residues
|
|
IKK‑beta (human): S181‑p, IKK‑beta (mouse): S181‑p, IKK‑beta (rat): S181‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
HT-29 (intestinal) [IKK-beta (human)], HT-29 (intestinal) [Nik (human)]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TNF
|
|
|
|
increase
|
|
|
IL-1b
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced
|
|
Comments:
A S181A mutation severely inhibited enzymatic activity; replacement of both S181 and S177 abolished IKK activation.
|